Ibogaine administration following repeated morphine administration upregulates myelination markers 2', 3'-cyclic nucleotide 3'-phosphodiesterase (CNP) and myelin basic protein (MBP) mRNA and protein expression in the internal capsule of Sprague Dawley rats.
Frontiers in Neuroscience 2024 Demi Govender, Leila Moloko, Maria Papathanasopoulos et al. 10 citations
Ibogaine is a psychedelic alkaloid being investigated as a possible treatment for opioid use disorder. Ibogaine has a multi-receptor profile with affinities for mu and kappa opioid as well as NMDA receptors amongst others. Due to the sparsity of research into ibogaine's effects on white matter integrity and given the growing evidence that opioid use disorder is characterized by white matter...
DOI: 10.3389/fnins.2024.1378841 (opens in new tab)
Full text (opens in new tab)
Opioid use disorder
Oligodendrocytes
Psychedelic medicine ibogaine
Psychedelic drug
+10